COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer (ConCab)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01541007
Recruitment Status : Completed
First Posted : February 29, 2012
Last Update Posted : November 2, 2015
Information provided by (Responsible Party):
Jeffrey Yachnin M.D., PhD., Karolinska University Hospital

Brief Summary:
Cabazitaxel has shown significant efficacy as second line chemotherapy after Docetaxel in men with metastatic castration resistant prostate cancer. This was demonstrated in the Tropic Study where Cabazitaxel showed survival superiority compared to mitoxantrone. Almost one in 4 patients treated with Cabazitaxel in this study required dose reductions or dose delays or stopped treatment due to toxicity. ConCab examines another scheduling for cabazitaxel to see if we can improve tolerability so that patients will receive a higher percentage of the treatment as planned.

Condition or disease Intervention/treatment Phase
Metastatic Castration Resistant Prostate Cancer Drug: Cabazitaxel Drug: weekly cabazitaxel Phase 2

Detailed Description:
ConCab compares the standard treatment of cabazitaxel 25 mg/m2 every three weeks with an experimental scheduling of 10 mg/m2 for 5 consecutive weeks of a 6 week cycle. In both study arms the planned cumulative dose of cabazitaxel at week 18 is 150 mg/m2. Our study aims to evaluate differences in the total received dose in relation to the planned dose as a measure of which of the 2 treatment schedules is superior.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Multicenter, Phase II Trial Comparing The Conventional 3 Weekly Schedule Of Cabazitaxel With A Weekly Regimen In Patients With Metastatic Castration Resistant Prostate Cancer
Study Start Date : April 2012
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Cabazitaxel

Arm Intervention/treatment
Active Comparator: Standard Cabazitaxel Schedule
Cabazitaxel 25 mg/m2 every three weeks
Drug: Cabazitaxel
25 mg/m2 every three weeks

Experimental: Weekly cabazitaxel schedule
cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
Drug: weekly cabazitaxel
10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks

Primary Outcome Measures :
  1. Relative cumulative dose of cabazitaxel at week 18 [ Time Frame: week 18 after start of treatment ]
    The primary endpoint compares the cumulative dose of cabazitaxel that is received relative to the planned dose at 18 weeks of therapy. The cumulative dose of cabazitaxel in relation to the expected dose is a reflection of both tolerability and efficacy. Patients stopping treatment due to disease progression prior to week 18 will have lower relative cumulative doses as will patients with poor tolerability due to dose reductions and delays.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: when the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date ]
    Overall survival is defined as the length of time from randomization to death from any cause

  2. Progression free survival [ Time Frame: when the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date ]
    Progression free survival is defined as the length of time from randomisation to the first documentation of one of the following: PSA progression or pain progression or death due to any cause or radiological disease progression

  3. PSA Response [ Time Frame: when the last enrolled patient has completed 18 weeks of therapy or has stopped therapy at an earlier date ]
    Only considered after 12 weeks of treatment. PSA response is defined as a 50% or greater decline in serum PSA from baseline given that baseline PSA is at least 10 ng/ml

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:¨

  • Histological confirmed prostate cancer
  • Macroscopic metastatic disease
  • Prior treatment with Docetaxel
  • Castration resistant disease defined as:Serum testosterone (< 0.5 ng/ml) and:
  • Increase in measurable disease (RECIST 1.1, see appendix 10) or
  • For non-measurable disease, the appearance of at least one new lesion on nuclear scintigraphy) or
  • A rising PSA from the previous reference value on 2 consecutive occasions at least one week apart
  • Written informed consent

Exclusion Criteria:

  • Less than 21 days since prior treatment with chemotherapy
  • Less than 14 days since radiotherapy or surgery to the start of cabazitaxel - Less than 4 weeks after stopping endocrine therapies including antiandrogen, abiraterone or other new agents.
  • Prior isotope therapy or radiotherapy to > 30% of bone marrow (whole pelvic radiotherapy is not an exclusion criteria)
  • Persistent adverse events from previous cancer therapies > grade 1 (CTCAE - Version 4.0) with the exception of alopecia. (With respect to peripheral neuropathy and nail changes grade 2 is acceptable)
  • ECOG performance status > 1
  • Known CNS malignancy
  • Within 6 months of randomization:

    • myocardial infarction,
    • unstable angina,
    • angioplasty,
    • bypass surgery,
    • stroke,
    • TIA, or
    • congestive heart failure NYHA class III or IV
  • Within 3 months prior to randomization:

    • treatment resistant peptic ulcer disease,
    • infectious or inflammatory bowel disease,
    • pulmonary embolism
    • Any severe acute or chronic medical condition that places the patient at increased risk of serious toxicity or interferes with the interpretation of study results
  • History of hypersensitivity to docetaxel or polysorbate 80
  • Inadequate organ and bone marrow function as evidenced by:

    • Hemoglobin < 9.0 g/dL
    • Absolute neutrophil count < 1.5 x 109/L,
    • Platelet count < 100 x 109/L,
    • AST/SGOT and/or ALT/SGPT > 1.5 x ULN;
    • Total bilirubin > 1.0 x ULN,
    • Serum creatinine > 1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance < 60 mL/min should be excluded ( for on-line calculation)
  • Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5. A one week wash out period is necessary for patients who are already on these treatments.
  • Patients with reproductive potential not implementing accepted and effective method of contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01541007

Layout table for location information
Deapartment of Oncology Karolinska University Hospital
Stockholm, Sweden, 171 76
Sponsors and Collaborators
Jeffrey Yachnin M.D., PhD.
Layout table for investigator information
Study Chair: Jeffrey R Yachnin, MD, PhD Karolinska University Hosptial

Layout table for additonal information
Responsible Party: Jeffrey Yachnin M.D., PhD., Director Clinical Trials Unit, Karolinska University Hospital Identifier: NCT01541007    
Other Study ID Numbers: 2011-004178-27
First Posted: February 29, 2012    Key Record Dates
Last Update Posted: November 2, 2015
Last Verified: October 2015
Keywords provided by Jeffrey Yachnin M.D., PhD., Karolinska University Hospital:
Prostate Cancer
Castration Resistant
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases